Benzinga | Apr 21, 2021 08:37AM EDT

Biocept Announces Commercial Launch Of CNSide Cerebrospinal Fluid Assay

Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, has announced the full commercial launch of CNSide(tm), its cerebrospinal fluid (CSF) assay designed to better detect and manage treatment of metastatic cancers involving the central nervous system (CNS). The assay, initially introduced in January 2020, has the ability to offer a timely and accurate method to diagnose disease, identify actionable biomarkers, and assess response to therapy, potentially impacting life expectancy and quality of life.